Montara Therapeutics is pioneering innovative therapies aimed at addressing neurological diseases through its proprietary BrainOnly™ platform. This technology is designed to enhance drug safety and efficacy by preventing peripheral toxicities that often limit the effectiveness of brain-penetrating therapies. By focusing on the central nervous system, Montara aims to tackle previously undruggable targets associated with neurodegenerative diseases and brain cancers. The BrainOnly platform allows for the development of two-drug combination therapies, where a brain-penetrant, target-specific drug is paired with a non-brain-penetrant universal peripheral blocker. This unique approach ensures that the active drug is concentrated in the brain while minimizing adverse effects in the periphery.

The BrainOnly platform is built on groundbreaking research from the University of California, San Francisco, and is designed to facilitate the discovery of novel small molecules while enhancing the profiles of existing drugs. By utilizing a universal FKBP12 binder that can be linked to various warheads, Montara can quickly adapt its therapies to target a wide range of neurological conditions, including Alzheimer’s disease, Parkinson’s disease, and brain tumors. This innovative strategy not only addresses significant unmet medical needs but also positions Montara Therapeutics as a leader in the development of safer and more effective treatments for complex brain-related disorders.

United States

We are Montara Therapeutics, a San Francisco–based precision-medicine neuroscience biotech startup. Our team boasts significant experience from successful biotech firms such as Mitokinin, Denali, and Soteria, supported by a world-class Scientific Advisory Board (SAB).

We bring a new approach to tackling challenging established targets, along with unique experience in developing enzyme activators and domain expertise in mitophagy.

Our mission is to create innovative therapies for diseases of the CNS, with a focus on precision medicine and genetically validated targets to enhance drug safety and efficacy.

Montara Therapeutics

Company Details